SBIR-STTR Award

Diagnostic Tool for the Point-of-Care Detection of Infection in Chronic Wounds
Award last edited on: 7/15/10

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$1,157,710
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Diane L Ellis-Busby

Company Information

ECI Biotech Inc (AKA: Expressive Constructs Inc)

85 Prescott Street
Worcester, MA 01605
   (508) 752-2209
   N/A
   www.ecibiotech.com
Location: Single
Congr. District: 02
County: Worcester

Phase I

Contract Number: 1R43GM079834-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2007
Phase I Amount
$208,311
Localized infection is a frequent complication of chronic wounds that interferes with the healing process and can lead to systemic infection, limb amputation, or death. Compounding the problem is an inability of the clinician to accurately detect localized infection by clinical observation, which is still the primary diagnostic method. This is because the usual signs of infection are masked by inflammation or the patients' underlying conditions or disease. The main objective of the proposed studies is to develop and validate a new assay that will enhance the ability of clinicians to detect chronic wound infection earlier and with more accuracy. The long-term goal is to incorporate this assay into a simple, inexpensive, point-of-care device to aid in diagnosis during a patient visit. This device will help individuals with chronic wounds receive appropriate treatment sooner, allow healing to resume, relieve their pain and discomfort, and avoid the spread of infection. The diagnostic device will be based on a novel detection method for pathogenic bacteria that was developed at ECI Biotech. This method measures the activity of protein-degrading enzymes (proteases) that infection-causing pathogens release into wound fluid. Since proteases are specific toward particular sites within proteins, ECI was able to design a single target peptide that contains cleavage sites for proteases from the most common wound pathogens. The resulting assay will detect the total number of pathogens but not discern between species. In previous studies, roughly 80% of clinical isolates from chronic wounds produced proteases in vitro that cleaved this target peptide. Also, over 90% of clinical samples taken directly from infected wounds were shown to have significant protease activity toward the target peptide. This work also revealed some cross-reactivity of the target peptide with the human neutrophil elastase (HNE), a host inflammatory protease present at high levels in chronic wounds. The first goal of this proposal is to alter the amino acid sequence of the target peptide to reduce interference by HNE while maintaining sensitivity toward bacterial proteases. The next goal is to demonstrate the efficacy of the new target peptide in detecting pathogens in chronic wounds. Protease activity in samples from patients with chronic wounds occupied by 105 or more pathogenic bacteria (infected) will be compared to those that are not (non-infected). In addition to verifying that this assay can differentiate infected from non- infected chronic wounds, this study will define a cutoff activity level that distinguishes the two. The last goal of our proposal is to correlate target peptide cleavage in vitro with known quantities of purified bacterial proteases. This information will be necessary to generate standards for conversion of proteolysis activity into a simple yes-or-no readout (visible by a color change) that will be used in the diagnostic device. Overall, the studies in this proposal will improve the assay for pathogen detection and demonstrate that it is suitable to aid in the early diagnosis of wound infection. /Relevance The goal of this research is to develop a simple, inexpensive diagnostic device to help clinicians determine if a chronic wound is infected at the point-of-care. By improving the ability for early detection of chronic wound infection, patients will receive appropriate treatment sooner and at a greater frequency. This will limit the spread of local wound infection, reduce the incidence of deep or systemic wound-related infections, and restore healing

Phase II

Contract Number: 2R44GM079834-02
Start Date: 6/1/07    Completed: 7/31/10
Phase II year
2008
(last award dollars: 2009)
Phase II Amount
$949,399

Infection is a major problem for the 5 to 6 million Americans with chronic wounds because it interferes with the normal healing process and increases the risk of serious complications that often necessitate limb amputation or result in death. A significant obstacle to the successful treatment of chronic wounds is the inability to correctly diagnose infection. Most clinicians still rely on visual signs and symptoms that are indicative of infection in acute or surgical wounds but have been proven to be inaccurate for diagnosis of infection in chronic wounds. The primary objective of this proposal is to optimize and validate a novel diagnostic test that will better enable physicians or nurses to detect chronic wound infection at the point-of- care. Our overall objective is produce a simple, single-use diagnostic device for hospitals, wound care clinics, outpatient centers, and long-term care facilities. The device will give a visible, yes-or-no result within 15 minutes when the bacterial concentration within the wound exceeds a level demonstrated to be indicative of infection. This would benefit public health by assisting individuals with chronic wounds to receive the appropriate treatment sooner, which will accelerate the healing process, relieve their suffering and discomfort, and lower the risk of infectious complications. Our Phase I objectives focused on the development of a functional diagnostic assay that was demonstrated to detect bacteria in chronic wounds with excellent diagnostic sensitivity and specificity relative to standard microbiological techniques. Our Phase II specific aims are focused on improvement and validation of the diagnostic test. The first aim is to evaluate a more accurate and reliable method of collecting tissue fluid from chronic wounds. This will help to reduce variability in the sample volume collected, which will improve diagnostic accuracy of the test. Our second objective is to change the assay readout from a quantitative ELISA format into a binary lateral flow-based test. An important step in this process is setting the appropriate threshold for the lateral flow line development using validated standards. Lastly, we plan to evaluate the diagnostic performance of test with samples from patients within the three major chronic wounds types: diabetic, pressure, and venous ulcers. Results of the diagnostic test will be compared to a reference standard for diagnosis of chronic wound infection to calculate the sensitivity and specificity. The data from this clinical study will evaluate the ability of the diagnostic test to detect chronic wound infection and will demonstrate clinical utility of the device.

Public Health Relevance:
The project goal is to develop a simple, inexpensive point-of-care diagnostic test to help clinicians rapidly determine if a chronic wound is infected. Earlier and more accurate infection diagnosis will allow patients to receive the appropriate treatment sooner, resulting in less pain and suffering and a lower risk of serious infection-related complications.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.